Tag:
cancer
Latest Headlines
Latest Headlines
Molecular Dx: Invitae drops prices as NIH starts 1,000-patient, molecular abnormalities cancer study
Newly public genetic information company Invitae has dropped prices for its genetic tests, just as the NIH says it will launch a study of the efficacy of cancer drugs by genetic mutation. Both are a testament to the rapidly evolving role of genetic information in patient treatment.
Singapore clinical group sees gene sequencing key in liver cancer treatment study
A Singapore-led clinical group has published a study of a novel approach to investigating how genes affect options to treat liver cancer, highlighting the city-state's growing role in oncology research.
Philips, MIT partner in $25M deal to develop innovative med tech, lighting
Royal Philips and the Massachusetts Institute of Technology (MIT) have partnered in a 5-year research alliance with a $25 million budget to develop novel product solutions in healthcare and lighting.
Express Scripts: Fight against cancer drug prices 'much bigger' than hep C
Express Scripts has been warning about a crackdown on cancer drug spending. Now, it's talking about how.
Roche's Ventana strikes companion diagnostic deal with Astellas Pharma
Roche's Ventana Medical Systems announced a companion diagnostic agreement centered around Astellas Pharma's cancer fighting ASP5878.
Roche grabs CAPP Medical to gain ground in cancer Dx
Roche snatched up genomics research outfit CAPP Medical to get its hands on the company's cancer detection platform, continuing its M&A streak and strengthening its foothold in cancer R&D.
Australia's reimbursement cost battle hits cancer drug access
Australia's reimbursement agency has lagged developed country counterparts in paying for newly approved new cancer therapies, highlighting problems at the tail end of a system that patients and industry complain is broken.
New Zealand researchers eye new route for efficacy of cancer drugs
New Zealand researchers say they may have discovered a route for drugs to be more effective against genetic stomach and lobular breast cancers in their early stages.
Japan's Eisai receives $40M in revised cancer therapy deal with Epizyme
Japan's Eisai sold the worldwide rights, excluding Japan, to Phase I/II cancer candidate EP-6438 to U.S.-based Epizyme for $40 million upfront, revising a 2011 agreement on discovery, development and commercialization of a therapy aimed at non-Hodgkin B-cell lymphoma and other cancers.
Amgen launches delivery device for automatic administration of its blockbuster Neulasta
Amgen just announced the debut of the Neulasta Delivery Kit to automatically deliver the medication for infection prevention among cancer patients about 27 hours after chemotherapy, thereby ensuring compliance with the dosing instructions.
